Managing residual sleep apnea after adenotonsillectomy: CPAP and repeat surgery

The AAO-HNS consensus (2023) recommends a multidisciplinary approach to children with persistent OSA after adenotonsillectomy (AT), including medical, surgical and device-based treatment. ^[1]

Assessment and diagnosis

The expert panel agreed that polysomnography (PSG) after treatment of persistent OSA is useful for guiding further management in asymptomatic children who had moderate or severe OSA before treatment. PSG is not required for asymptomatic children who had mild OSA before treatment. Assessment for craniofacial anomalies by a dentist or maxillofacial surgeon, as well as assessment for adenoid regrowth (especially in children with Down syndrome), was considered useful. ^[1]

Medical therapy

• Intranasal corticosteroids (INCS) — strong consensus in favor of their use for mild or moderate persistent OSA with nasal obstruction. In severe OSA, INCS are less effective as monotherapy. Response to treatment should be assessed objectively after 6 weeks ^[1]
• Montelukast — considered effective for mild/moderate persistent OSA, especially in children without prior behavioral or mood disorders. The FDA warning about neuropsychiatric side effects must be discussed with the family ^[1]
• Observation — considered reasonable for asymptomatic children with mild persistent OSA. The CHAT study showed spontaneous improvement in 46% of children without treatment ^[1]

CPAP therapy

The consensus supports CPAP as a reasonable treatment option. Pressure settings are determined by in-lab titration. For adolescents aged 13 and older, automatic CPAP (AutoPAP) is acceptable. Adherence remains the main barrier; behavioral modification can improve use of the device. ^[1]

Surgical treatment

Consensus was reached on 8 surgical interventions aimed at specific sites of obstruction identified by DISE (drug-induced sleep endoscopy): ^[1]

• Lingual tonsillectomy — for lingual tonsil hypertrophy
• Inferior turbinate reduction — for turbinate hypertrophy
• Supraglottoplasty — for sleep-dependent laryngomalacia
• Expansion pharyngoplasty — for lateral pharyngeal wall collapse
• Mandibulomaxillary distraction — for upper/lower jaw deficiency
• Hypoglossal nerve stimulation (HGNS) — for severe persistent OSA in children with Down syndrome
• Craniofacial surgery — for craniofacial anomalies
• Tracheostomy — for severe OSA when other methods are ineffective or contraindicated

No consensus was reached on septoplasty, posterior midline glossectomy, tongue base reduction and epiglottopexy because of limited data in children. ^[1]

Prevalence and risk factors of persistent OSA

Persistent OSA after AT is seen in up to 40% of children overall, but the rate varies considerably by population: 50% in children with obesity, 50% in Down syndrome and 10–15% with initially severe OSA (AHI ≥10/hour). Given the global epidemic of childhood obesity and improved survival of children with complex conditions, the number of children with persistent OSA is steadily growing. ^[2]

CPAP therapy: effectiveness and adherence

CPAP effectively reduces the severity of OSA: in observational studies, the median AHI fell from 12.1 to 0.8 events/hour, and oxygen saturation rose from 87% to 93%. School performance improved in all children for whom data were available, and hyperactivity/behavioral problems fell from 18% to 7%. ^[2]

However, adherence remains the main barrier: a meta-analysis of 34 studies (21,737 patients) showed average adherence of only 46.6%. Factors associated with better adherence: younger age, lower BMI and higher AHI. Side effects include mask fitting problems (24%), CO₂ retention or central apneas (25% in one study), and refusal by the child or parents. ^[2][3]

The ATS guideline (2024) recommends a first visit 30–90 days after starting CPAP, regular downloads of device data to assess adherence, and involving a behavioral psychologist if there are problems with adaptation. The goal is to use CPAP for the entire sleep period. ^[2]

Orthodontic treatment: rapid maxillary expansion (RME)

RME is recommended by the ATS (conditional recommendation) for children with persistent OSA and a narrow upper jaw (a high, narrow palate, often with a crossbite), ideally at age 6–13. In studies, RME after AT further reduced the AHI from 4.9 to 0.9 events/hour, and the combined AHI improvement was 3.3 events/hour (95% CI 1.8–4.8). A meta-analysis confirmed a significant reduction in AHI and an increase in minimum SaO₂ both immediately after treatment and at 6 and 12 months. ^[2][4]

Hypoglossal nerve stimulation (HGNS)

HGNS is a promising method for children with Down syndrome and severe refractory OSA. The FDA has approved HGNS implantation for children with Down syndrome from age 13. Long-term results of a prospective multicenter study (42 adolescents with Down syndrome) showed: ^[5][6]

• Response rate (AHI reduction of 50% or more) — 69.7% at 1 year and 87.9% at long-term follow-up (4 years on average)
• Average AHI reduction — 15.7 events/hour at long-term follow-up
• High compliance and a lasting improvement in quality of life

A successful case of HGNS implantation in a 4-year-old child with Down syndrome and refractory OSA has also been described, which extends the potential age range for this treatment. ^[7]

Lingual tonsillectomy

The lingual tonsil is one of the most common sites of obstruction in persistent OSA, especially in children with Down syndrome. A meta-analysis showed an average AHI reduction of 8.9 events/hour after lingual tonsillectomy, with consistent improvement in all included studies. Medical comorbidities (hypotonia, Down syndrome, neuromuscular diseases) did not affect the results of lingual tonsillectomy, but they significantly worsened the outcomes of supraglottoplasty. ^[8][9][10]

Management algorithm

A practical approach to a child with persistent OSA after AT:

• Confirm the diagnosis — PSG 6–8 weeks after surgery (for moderate/severe OSA or persistent symptoms)
• Assess severity — mild, asymptomatic OSA → observation ± INCS ± montelukast; moderate OSA → INCS + montelukast, assessment of craniofacial features, DISE; severe OSA → DISE to identify sites of obstruction → targeted surgery and/or CPAP
• Multidisciplinary assessment — ENT, sleep specialist, orthodontist and, if needed, a maxillofacial surgeon
• Correct modifiable factors — weight loss for obesity, treatment of allergic rhinitis, control of GERD